The bone anabolic therapy

Aging Clinical and Experimental Research

Volumn 25, Issue 1 SUPPL., 2013, Pages

  Nardi, A ^a   Ventura, L ^b   Cozzi, L ^a   Tonini, G ^a   Zennaro, R ^c   Celi, M ^d   Ramazzina, E ^a  

^a ULSS 18   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c ULSS 19   (Italy)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Parathyroid hormone (PTH); Teriparatide (TPTD); Vertebral compression fractures (VCFs)

Indexed keywords

PARATHYROID HORMONE[1-34];

BONE ANABOLIC THERAPY; CONFERENCE PAPER; CORTICAL BONE; FRACTURE; FRACTURE NONUNION; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PSEUDARTHROSIS;

ARTHRITIS; BONE AND BONES; BONE DENSITY; FEMALE; FRACTURE FIXATION, INTERNAL; FRACTURE HEALING; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; POSTMENOPAUSE; RISK; TERIPARATIDE;

EID: 84886818065     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-013-0133-7     Document Type: Conference Paper

References (15)

1. Poole KES et al (2001) Targeted regeneration of bone in the osteoporotic human femur. PLoS ONE 6:e16190. | http://www.plosone.org. Accessed 1 January 2011 |
2. Andrews EB et al (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27(12):2429-2437
3. Borggrefe J, Graeff C, Nickelsen T et al (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS Study. J Bone Miner Res 25(3):472-481
4. Graeff C, Chevalier Y, Charlebois M, Varga P et al (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24(10):1672-1680
5. Nardi A, Tarantino U, Ventura L et al (2011) The domino effect: the rule of mechanical factors. Clin Case Miner Bone Metab 8(2):38-42
6. Bouxsein M, Chen P, Glass E, Kallmes D et al (2009) Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis: results from two randomized controlled trials. J Bone Joint Surg Am 91:1329-1338
7. Alkhiary Y, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731-741. doi: 10.2106/JBJS.D.02115
8. Kaback LA, Soung D, Naik A et al (2008) Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem 105:219-226
9. Aspenberg P, Genant HK, Johansson T et al (2010) Teriparatide for acceleration of fracture repair in humans: a prospective randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25(2):404-414
10. Pietrogrande L, Raimondo E (2013) Teriparatide in the treatment of non-unions: scientific and clinical evidences. Injury Int J Care Injured 44(Suppl 1):S54-S57. doi: 10.1016/S0020-1383(13)70013-5
11. Corradini C, Macchia M, Malagoli E (2010) Enhanced healing of lateral femoral neck fractures in early women with teriparatide; new therapeutic horizon. Osteoporos Int 21:S177-S178
12. Lee YK, Ha YC, Koo NU (2012) Teriparatide, a non surgical solution for femoral nonunion? A report of three cases. Osteoporos Int 23(12):2897-2900
13. Cherie YC, Roger MD et al (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360-365
14. Gomberg SJ, Wustrack R, Napoli N, Arnaud C et al (2011) Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 96(6):1627-1632
15. Kwon Y-D et al (2012) Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 23:2721-2725